<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 02 Sep 2024 14:09:37 +0000</lastbuilddate>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 2. doi: 10.1161/CIRCULATIONAHA.124.069917. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39221566</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069917>10.1161/CIRCULATIONAHA.124.069917</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221566</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tabassome Simon</dc:creator>
<dc:creator>Brandon M Herbert</dc:creator>
<dc:creator>Maria Mori Brooks</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Shahab Ghafghazi</dc:creator>
<dc:creator>Claire Bouleti</dc:creator>
<dc:creator>Howard A Cooper</dc:creator>
<dc:creator>Eric L McCamant</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Herbert D Aronow</dc:creator>
<dc:creator>J Dawn Abbott</dc:creator>
<dc:creator>Caroline Alsweiler</dc:creator>
<dc:creator>Marnie Bertolet</dc:creator>
<dc:creator>Dean A Fergusson</dc:creator>
<dc:creator>Andrew M Goldsweig</dc:creator>
<dc:creator>Paul C Hébert</dc:creator>
<dc:creator>Jeffrey L Carson</dc:creator>
<dc:creator>MINT Trial Investigators</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial</dc:title>
<dc:identifier>pmid:39221566</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069917</dc:identifier>
</item>
<item>
<title>What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3213. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39221517</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3213>10.1001/jamacardio.2024.3213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221517</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques</dc:title>
<dc:identifier>pmid:39221517</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3213</dc:identifier>
</item>
<item>
<title>Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3200. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardial infarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified as segments with plaque burden 40% or greater defined by intravascular ultrasound (IVUS). IVUS, near-infrared spectroscopy, and optical coherence tomography images at baseline and the 52-week follow-up were manually matched by readers blinded to treatment allocation. Data for this study were analyzed from October 2022 to November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Alirocumab or placebo in addition to high-intensity statin therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Lesion-level imaging outcome measures, including high-risk plaque characteristics and phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 245 patients in whom lesions were found, 118 were in the alirocumab group (mean [SD] age, 58.2 [10.0] years; 101 [85.6%] male and 17 [14.4%] female) and 127 in the placebo group (mean [SD] age, 57.7 [8.8] years; 104 [81.9%] male and 23 [18.1%] female). Overall, 591 lesions were included: 287 lesions (118 patients, 214 vessels) in the alirocumab group and 304 lesions (127 patients, 239 vessels) in the placebo group. Lesion-level mean change in percent atheroma volume (PAV) was -4.86% with alirocumab vs -2.78% with placebo (difference, -2.02; 95% CI, -3.00 to -1.05; P &lt; .001). At the minimum lumen area (MLA) site, mean change in PAV was -10.14% with alirocumab vs -6.70% with placebo (difference, -3.36; 95% CI, -4.98 to -1.75; P &lt; .001). MLA increased by 0.15 mm2 with alirocumab and decreased by 0.07 mm2 with placebo (difference, 0.21; 95% CI, 0.01 to 0.41; P = .04). Among 122 lipid-rich lesions, 34 of 55 (61.8%) in the alirocumab arm and 27 of 67 (41.8%) in the placebo arm showed a less lipid-rich plaque phenotype at follow-up (P = .03). Among 63 lesions with thin-cap fibroatheroma at baseline, 8 of 26 (30.8%) in the alirocumab arm and 3 of 37 (8.1%) in the placebo arm showed a fibrous/fibrocalcific plaque phenotype at follow-up (P = .02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03067844.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39221516</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3200>10.1001/jamacardio.2024.3200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221516</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Flavio G Biccirè</dc:creator>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Konstantinos C Koskinas</dc:creator>
<dc:creator>Yasushi Ueki</dc:creator>
<dc:creator>Jonas Häner</dc:creator>
<dc:creator>Hiroki Shibutani</dc:creator>
<dc:creator>Jacob Lønborg</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Juan F Iglesias</dc:creator>
<dc:creator>Tatsuhiko Otsuka</dc:creator>
<dc:creator>George C M Siontis</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Christoph Kaiser</dc:creator>
<dc:creator>Maria Ambühl</dc:creator>
<dc:creator>Laura Morf</dc:creator>
<dc:creator>Anna S Ondracek</dc:creator>
<dc:creator>Robert-Jan van Geuns</dc:creator>
<dc:creator>David Spirk</dc:creator>
<dc:creator>Joost Daemen</dc:creator>
<dc:creator>François Mach</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Irene Lang</dc:creator>
<dc:creator>Sylvain Losdat</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial</dc:title>
<dc:identifier>pmid:39221516</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3200</dc:identifier>
</item>
<item>
<title>Echoes of Concern-AI and Moral Agency in Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39221501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 2. doi: 10.1001/jamacardio.2024.3512. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39221501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39221501</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3512>10.1001/jamacardio.2024.3512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39221501</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah C Hull</dc:creator>
<dc:creator>Joseph J Fins</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Echoes of Concern-AI and Moral Agency in Medicine</dc:title>
<dc:identifier>pmid:39221501</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3512</dc:identifier>
</item>
<item>
<title>Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39219447/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women with endometriosis have a higher associated long-term risk of cardiovascular outcomes compared with controls. Despite subtle absolute risk-differences, the high prevalence of endometriosis underscores the importance of these findings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae563. doi: 10.1093/eurheartj/ehae563. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Endometriosis, a systemic gynecological disease affecting 10% of women in reproductive age, shares pathophysiological characteristics with cardiovascular disease. However, data on the relationship between endometriosis and cardiovascular outcomes are scarce, prompting this study to address the knowledge-gap.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using Danish nationwide registries, women diagnosed with endometriosis (1977-2021) were identified and matched with controls in a 1:4 ratio based on year of birth. The primary outcome was a composite of acute myocardial infarction and ischemic stroke. The secondary outcomes were arrhythmias, heart failure, and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 60,508 women with endometriosis and 242,032 matched controls were included (median age 37.3 years). Women with endometriosis were more comorbid and used more medications than controls. The incidence rates of the composite outcomes were 3.2 (95% confidence interval [CI] 3.2-3.3) and 2.7 (95% CI 2.7-2.8) per 1000 person-years among women with and without endometriosis, respectively. Women with endometriosis had a significantly higher associated rate of the composite outcome compared with controls (unadjusted hazard ratio [HR] 1.18 [95% CI 1.14-1.23], adjusted HR 1.15 [95% CI 1.11-1.20]). Likewise, women with endometriosis were also at significantly increased associated risk of arrhythmias (unadjusted HR 1.24 [95% CI 1.20-1.28], adjusted HR 1.21 [95% CI 1.17-1.25]) and heart failure (unadjusted HR 1.16 [95% CI 1.09-1.22], adjusted HR 1.11 [95% CI 1.05-1.18]) but at decreased risk of mortality (unadjusted HR 0.95 [95% CI 0.92-0.97], adjusted HR 0.93 [95% CI 0.91-0.96]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women with endometriosis have a higher associated long-term risk of cardiovascular outcomes compared with controls. Despite subtle absolute risk-differences, the high prevalence of endometriosis underscores the importance of these findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39219447/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39219447</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae563>10.1093/eurheartj/ehae563</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39219447</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Eva Havers-Borgersen</dc:creator>
<dc:creator>Dorthe Hartwell</dc:creator>
<dc:creator>Charlotte Ekelund</dc:creator>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Christine Holgersson</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Emil L Fosbøl</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study</dc:title>
<dc:identifier>pmid:39219447</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae563</dc:identifier>
</item>
<item>
<title>Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39219338/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 2:ehae610. doi: 10.1093/eurheartj/ehae610. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39219338/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39219338</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae610>10.1093/eurheartj/ehae610</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39219338</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Steffen Desch</dc:creator>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Ibrahim Akin</dc:creator>
<dc:creator>Michael Behnes</dc:creator>
<dc:creator>Daniel Duerschmied</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Amir Abbas Mahabadi</dc:creator>
<dc:creator>Ralf Lehmann</dc:creator>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Tobias Graf</dc:creator>
<dc:creator>Tim Seidler</dc:creator>
<dc:creator>Andreas Schuster</dc:creator>
<dc:creator>Tharusan Thevathasan</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Marcus Hennersdorf</dc:creator>
<dc:creator>Stephan Fichtlscherer</dc:creator>
<dc:creator>Ingo Voigt</dc:creator>
<dc:creator>Melchior Seyfarth</dc:creator>
<dc:creator>Stefan John</dc:creator>
<dc:creator>Sebastian Ewen</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Eike Tigges</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Leonhard Bruch</dc:creator>
<dc:creator>Christian Jung</dc:creator>
<dc:creator>Jutta Franz</dc:creator>
<dc:creator>Philipp Lauten</dc:creator>
<dc:creator>Marko Noc</dc:creator>
<dc:creator>Georg Fuernau</dc:creator>
<dc:creator>Hans-Josef Feistritzer</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Eva Kirchhof</dc:creator>
<dc:creator>Taoufik Ouarrak</dc:creator>
<dc:creator>Steffen Schneider</dc:creator>
<dc:creator>Anne Freund</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial</dc:title>
<dc:identifier>pmid:39219338</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae610</dc:identifier>
</item>
<item>
<title>Six substudies from the semaglutide trials: Identifying mechanisms of benefit and whom to treat</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39218241/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08250-0. doi: 10.1016/j.jacc.2024.08.038. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39218241/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39218241</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.038>10.1016/j.jacc.2024.08.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39218241</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Six substudies from the semaglutide trials: Identifying mechanisms of benefit and whom to treat</dc:title>
<dc:identifier>pmid:39218241</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.038</dc:identifier>
</item>
<item>
<title>The Obesity Revolution Comes to Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39218240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08254-8. doi: 10.1016/j.jacc.2024.08.042. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39218240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39218240</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.042>10.1016/j.jacc.2024.08.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39218240</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Obesity Revolution Comes to Cardiology</dc:title>
<dc:identifier>pmid:39218240</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.042</dc:identifier>
</item>
<item>
<title>Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae589. doi: 10.1093/eurheartj/ehae589. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Neoatherosclerosis is a leading cause of late (>;1 year) stent failure following drug-eluting stent implantation. The role of biodegradable (BP) versus durable polymer (DP) drug-eluting stents on long-term occurrence of neoatherosclerosis remains unclear. Superiority of biodegradable against durable polymer current generation thin-strut everolimus-eluting stent (EES) was tested by assessing the frequency of neoatherosclerosis 3 years after primary percutaneous coronary intervention (pPCI) among patients with ST-segment elevation myocardial infarction (STEMI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The randomized controlled, multicentre (Japan and Switzerland) CONNECT trial (NCT03440801) randomly (1:1) assigned 239 STEMI patients to pPCI with BP-EES or DP-EES. The primary endpoint was the frequency of neoatherosclerosis assessed by optical coherence tomography (OCT) at 3 years. Neoatherosclerosis was defined as fibroatheroma or fibrocalcific plaque or macrophage accumulation within the neointima.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 239 STEMI patients randomized, 236 received pPCI with stent implantation (119 BP-EES; 117 DP-EES). A total of 178 patients (75%; 88 in the BP-EES group and 90 in the DP-EES group) underwent OCT assessment at 3 years. Neoatherosclerosis did not differ between the BP-EES (11.4%) and DP-EES (13.3%; odds ratio 0.83, 95% confidence interval 0.33-2.04, p=0.69). There were no differences in the frequency of fibroatheroma (BP-EES 9.1% vs DP-EES 11.1%, p=0.66) or macrophage accumulation (BP-EES 4.5% vs DP-EES 3.3%, p=0.68), and no fibrocalcific neoatherosclerosis was observed. Rates of target lesion failure did not differ between groups (BP-EES 5.9% vs DP-EES 6.0%, p=0.97).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Use of BP-EES for primary PCI in patients presenting with STEMI was not superior to DP-EES regarding frequency of neoatherosclerosis at 3 years.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217617</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae589>10.1093/eurheartj/ehae589</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217617</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Masanori Taniwaki</dc:creator>
<dc:creator>Jonas Dominik Häner</dc:creator>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Yohei Ohno</dc:creator>
<dc:creator>Kazuyuki Yahagi</dc:creator>
<dc:creator>Yoshiharu Higuchi</dc:creator>
<dc:creator>George C M Siontis</dc:creator>
<dc:creator>Kenji Ando</dc:creator>
<dc:creator>Stefan Stortecky</dc:creator>
<dc:creator>Nobuaki Suzuki</dc:creator>
<dc:creator>Laura Morf</dc:creator>
<dc:creator>Naoki Watanabe</dc:creator>
<dc:creator>Jonas Lanz</dc:creator>
<dc:creator>Yasushi Ueki</dc:creator>
<dc:creator>Tatsuhiko Otsuka</dc:creator>
<dc:creator>Flavio Giuseppe Biccirè</dc:creator>
<dc:creator>Masami Sakurada</dc:creator>
<dc:creator>Sylvain Losdat</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial</dc:title>
<dc:identifier>pmid:39217617</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae589</dc:identifier>
</item>
<item>
<title>Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year Olds to Detect Atrial Fibrillation -STROKESTOP II</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>Background: Guidelines have suggested screening for atrial fibrillation to enable early treatment and avoid downstream negative clinical events. We aimed to determine if atrial fibrillation screening potentially enhanced by NT-proBNP would reduce stroke or systemic embolism incidence as compared to in a control group and to determine if it was safe for those with low NT-proBNP concentrations to forfeit prolonged screening. Methods: In this randomized controlled trial all 75/76-year-old...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 1. doi: 10.1161/CIRCULATIONAHA.124.071176. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Guidelines have suggested screening for atrial fibrillation to enable early treatment and avoid downstream negative clinical events. We aimed to determine if atrial fibrillation screening potentially enhanced by NT-proBNP would reduce stroke or systemic embolism incidence as compared to in a control group and to determine if it was safe for those with low NT-proBNP concentrations to forfeit prolonged screening. <b>Methods:</b> In this randomized controlled trial all 75/76-year-old individuals in Stockholm Region, Sweden were randomized 1:1 to be invited to screening or serve as a control group. NT-proBNP concentration were measured and a single-lead-ECG registered only once if NT-proBNP&lt;125ng/L, whereas if NT-proBNP≥125 ng/L participants underwent prolonged screening, recording single-lead ECGs four times daily for two weeks. If atrial fibrillation was detected, treatment was initiated. Baseline and outcome data were collected from Swedish National Registries. <b>Results:</b> In total 28,712 individuals were randomized, after exclusion of death and emigration 13,905 remained in the intervention group, 13,884 in the control group. Participation rate in the intervention group was 49.2% (6,843/13,905). Participants in the high NT-proBNP group (NT-proBNP≥125 ng/L) without prior atrial fibrillation constituted 60% of the total and underwent prolonged screening. New AF was detected in 2.4% (165/6,843) in the intervention group. There was no difference in AF prevalence or oral anticoagulant treatment between the intervention and the control group after five years follow-up. After a median of 5.1 years (IQR 5.0-5.8) there was no difference in the primary outcome of stroke or systemic embolism between the intervention group and the control group, HR: 0.96 (95% CI 0.86-1.06). The low NT-proBNP-group had significantly fewer strokes or systemic emboli than the control group, HR: 0.59 (95% CI 0.46-0.74), p&lt;0.001. In the high NT-proBNP group the risk of stroke or systemic embolism was higher compared to the low NT-proBNP group, HR: 1.57 (95% CI 1.22-2.02), p=0.001. <b>Conclusions:</b> In this population-based screening trial for atrial fibrillation using NT-proBNP for screening enhancement, there was no difference in risk of stroke or systemic embolism for the intervention group compared to controls. Participation was moderate. The use of NT-proBNP for screening enhancement was safe in identifying low-risk participants. <b>Clinical Trial Registration:</b> www.clinicaltrials.gov; NCT02743416.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217615</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071176>10.1161/CIRCULATIONAHA.124.071176</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217615</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Katrin Kemp Gudmundsdottir</dc:creator>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Leif Friberg</dc:creator>
<dc:creator>Tove Hygrell</dc:creator>
<dc:creator>Viveka Frykman</dc:creator>
<dc:creator>Faris Al-Khalili</dc:creator>
<dc:creator>Ziad Hijazi</dc:creator>
<dc:creator>Marten Rosenqvist</dc:creator>
<dc:creator>Johan Engdahl</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year Olds to Detect Atrial Fibrillation -STROKESTOP II</dc:title>
<dc:identifier>pmid:39217615</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071176</dc:identifier>
</item>
<item>
<title>Microvascular resistance reserve: impact on health status and myocardial perfusion after revascularization in chronic coronary syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217607/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with moderate coronary stenoses, MRR seems to predict symptomatic and perfusion benefit of revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae604. doi: 10.1093/eurheartj/ehae604. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The microvascular resistance reserve (MRR) is a novel invasive index of the microcirculation, which is independent of epicardial stenoses, and MRR has both diagnostic and prognostic implications. This study investigates whether MRR is associated with health status outcomes by revascularization in patients with moderate coronary stenoses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients with stable chest pain and moderate (30-90% diameter) stenoses on invasive coronary angiography (n=222) underwent invasive physiology assessment. Revascularization was performed by guideline recommendations. At baseline and follow-up, health status and myocardial perfusion were assessed by Seattle Angina Questionnaire (SAQ) and positron emission tomography. The primary endpoint was freedom from angina at follow-up with secondary endpoints including changes in health status by SAQ domains and myocardial perfusion by MRR and revascularization status. Low MRR was defined as ≤3.0.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Freedom from angina occurred in 38/173 patients. In multivariate analyses, MRR was associated with freedom from angina at follow-up (odds ratio 0.860, 95% confidence interval 0.740-0.987). By MRR and revascularization groups, patients with normal MRR who did not undergo revascularization, and patients with abnormal MRR who underwent revascularization, improved health status of angina frequency (mean difference SAQ angina frequency score 8.5 [3.07-13.11] and 13.5 [2.82-23.16], respectively). For both groups, health status of physical limitation (mean difference in SAQ physical limitation score 9.7 [4.79-11.93] and 8.7 [0.53-13.88], respectively) and general health status (mean difference in SAQ summary score 9.3 [5.18-12.50] and 10.8 [2.51-17.28], respectively) also improved. Only patients with abnormal MRR who underwent revascularization improved myocardial perfusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with moderate coronary stenoses, MRR seems to predict symptomatic and perfusion benefit of revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217607/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217607</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae604>10.1093/eurheartj/ehae604</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217607</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Laust Dupont Rasmussen</dc:creator>
<dc:creator>Jelmer Westr</dc:creator>
<dc:creator>Salma Raghad Karim</dc:creator>
<dc:creator>Jonathan Nørtoft Dahl</dc:creator>
<dc:creator>Jacob Hartmann Søby</dc:creator>
<dc:creator>June Anita Ejlersen</dc:creator>
<dc:creator>Lars Christian Gormsen</dc:creator>
<dc:creator>Ashkan Eftekhari</dc:creator>
<dc:creator>Evald Høj Christiansen</dc:creator>
<dc:creator>Morten Bøttcher</dc:creator>
<dc:creator>Simon Winther</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Microvascular resistance reserve: impact on health status and myocardial perfusion after revascularization in chronic coronary syndrome</dc:title>
<dc:identifier>pmid:39217607</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae604</dc:identifier>
</item>
<item>
<title>Bailout glycoprotein IIb/IIIa inhibitors for coronary microvascular obstruction: guideline-indicated, but does harm outweigh benefit?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217606/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae601. doi: 10.1093/eurheartj/ehae601. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217606/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217606</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae601>10.1093/eurheartj/ehae601</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217606</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jasmine Latter</dc:creator>
<dc:creator>Peter McCartney</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bailout glycoprotein IIb/IIIa inhibitors for coronary microvascular obstruction: guideline-indicated, but does harm outweigh benefit?</dc:title>
<dc:identifier>pmid:39217606</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae601</dc:identifier>
</item>
<item>
<title>Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction and Angiographic Microvascular Obstruction: The REVERSE-FLOW Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae587. doi: 10.1093/eurheartj/ehae587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The investigator-initiated, international, multicenter REVERSE-FLOW trial randomized 120 patients with AMI and Thrombolysis In Myocardial Infarction flow grade ≤2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size (%LV) assessed by cardiac magnetic resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day adverse clinical events. The trial is registered with ClinicalTrials.gov: NCT02739711.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The population was predominantly male (76.7%) with a median age of 66 years and ST-elevation myocardial infarction in 73.3% of patients. Clinical and angiographic characteristics were well balanced between the cohorts. Patients in the treatment group (n=62) received eptifibatide (n=41) or tirofiban (n=21). Infarct size assessed by CMR imaging was similar in both study groups (25.4% of left ventricular mass [LV] vs. 25.2%LV; p=0.386). However, the number of patients with evidence of CMR-derived MVO (74.5% vs. 92.2%; p=0.017) and the extent of MVO (2.1%LV vs. 3.4%LV; p=0.025) were significantly reduced in the GP IIb/IIIa inhibitor group compared to controls. Thirty-day outcome showed an increased bleeding risk after GP IIb/IIIa inhibitor administration restricted to non-life-threatening bleedings (22.6% vs. 6.9%; p=0.016) without differences in all-cause mortality (4.8% vs. 3.4%; p=0.703).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Bailout GP IIb/IIIa inhibition in AMI patients with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO and led to an increase in non-fatal bleeding events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217605</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae587>10.1093/eurheartj/ehae587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217605</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ingo Eitel</dc:creator>
<dc:creator>Roza Saraei</dc:creator>
<dc:creator>Dominik Jurczyk</dc:creator>
<dc:creator>Andreas Fach</dc:creator>
<dc:creator>Rainer Hambrecht</dc:creator>
<dc:creator>Harm Wienbergen</dc:creator>
<dc:creator>Christian Frerker</dc:creator>
<dc:creator>Tobias Schmidt</dc:creator>
<dc:creator>Abdelhakim Allali</dc:creator>
<dc:creator>Alexander Joost</dc:creator>
<dc:creator>Christoph Marquetand</dc:creator>
<dc:creator>Thomas Kurz</dc:creator>
<dc:creator>Philip Haaf</dc:creator>
<dc:creator>Gregor Fahrni</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:creator>Steffen Desch</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:creator>Thomas Stiermaier</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction and Angiographic Microvascular Obstruction: The REVERSE-FLOW Trial</dc:title>
<dc:identifier>pmid:39217605</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae587</dc:identifier>
</item>
<item>
<title>Fasting vs no fasting prior to catheterisation laboratory procedures: the SCOFF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients undergoing cardiac catheterisation and CIED related procedures, no fasting was non-inferior and superior to fasting for the primary composite outcome of aspiration pneumonia, hypotension, hyperglycaemia and hypoglycaemia. Patient satisfaction scores were significantly better with no fasting. This supports removing fasting requirements for patients undergoing cardiac catheterisation laboratory procedures that require conscious sedation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae573. doi: 10.1093/eurheartj/ehae573. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current guidelines recommend 6 hours of solid food and 2 hours of clear liquid fasting for patients undergoing cardiac procedures with conscious sedation. There are no data to support this practice, and previous single centre studies support the safety of removing fasting requirements. The objective of this study was to determine the non-inferiority of a no fasting strategy to fasting prior to cardiac catheterisation procedures which require conscious sedation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a multicentre, investigator-initiated, non-inferiority randomised trial conduced in Australia with a prospective open label blinded endpoint design. Patients referred for coronary angiography, percutaneous coronary intervention or cardiac implantable electronic device (CIED) related procedures were enrolled. Patients were randomised 1:1 to fasting as normal (6 hours solid food and 2 hours clear liquid) or no fasting requirements (encouraged to have regular meals but not mandated to do so). Recruitment occurred from 2022 to 2023. The primary outcome was a composite of aspiration pneumonia, hypotension, hyperglycaemia and hypoglycaemia assessed with a Bayesian approach. Secondary outcomes included patient satisfaction score, new ventilation requirement (non-invasive and invasive), new intensive care unit admission, 30-day readmission, 30-day mortality, 30-day pneumonia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 716 patients were randomised with 358 in each group. Those in the fasting arm had significantly longer solid food fasting (13.2 versus 3.0 hours, Bayes factor >;100 indicating extreme evidence of difference) and clear liquid fasting times (7.0 versus 2.4 hours, Bayes factor >;100). The primary composite outcome occurred in 19.1% of patients in the fasting arm and 12.0% of patients in the no fasting arm. The estimate of the mean posterior difference in proportions in the primary composite outcome was -5.2% (95% CI -9.6 to -0.9, ) favouring no fasting. This result confirms non-inferiority (posterior probability >;99.5%) and superiority (posterior probability 99.1%) of no fasting for the primary composite outcome. The no fasting arm had improved patient satisfaction scores with a posterior mean difference of 4.02 points (95% CI 3.36 to 4.67, Bayes factor >;100). Secondary outcome events were similar.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients undergoing cardiac catheterisation and CIED related procedures, no fasting was non-inferior and superior to fasting for the primary composite outcome of aspiration pneumonia, hypotension, hyperglycaemia and hypoglycaemia. Patient satisfaction scores were significantly better with no fasting. This supports removing fasting requirements for patients undergoing cardiac catheterisation laboratory procedures that require conscious sedation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217604</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae573>10.1093/eurheartj/ehae573</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217604</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>David Ferreira</dc:creator>
<dc:creator>Jack Hardy</dc:creator>
<dc:creator>William Meere</dc:creator>
<dc:creator>Lloyd Butel-Simoes</dc:creator>
<dc:creator>Shanathan Sritharan</dc:creator>
<dc:creator>Max Ray</dc:creator>
<dc:creator>Matthew French</dc:creator>
<dc:creator>Michael McGee</dc:creator>
<dc:creator>Simon O'Connor</dc:creator>
<dc:creator>Nicholas Whitehead</dc:creator>
<dc:creator>Stuart Turner</dc:creator>
<dc:creator>Paul Healey</dc:creator>
<dc:creator>Allan Davies</dc:creator>
<dc:creator>Gwilym Morris</dc:creator>
<dc:creator>Nicholas Jackson</dc:creator>
<dc:creator>Malcolm Barlow</dc:creator>
<dc:creator>Tom Ford</dc:creator>
<dc:creator>Sarah Leask</dc:creator>
<dc:creator>Christopher Oldmeadow</dc:creator>
<dc:creator>John Attia</dc:creator>
<dc:creator>Aaron Sverdlov</dc:creator>
<dc:creator>Nicholas Collins</dc:creator>
<dc:creator>Andrew Boyle</dc:creator>
<dc:creator>Bradley Wilsmore</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fasting vs no fasting prior to catheterisation laboratory procedures: the SCOFF trial</dc:title>
<dc:identifier>pmid:39217604</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae573</dc:identifier>
</item>
<item>
<title>Complete vs. Culprit-Only Revascularization in Older Patients with ST-segment Elevation Myocardial Infarction: An Individual Patient Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217603/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>Background: Complete revascularization is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. The Functional Assessment in Elderly MI Patients with Multivessel Disease (FIRE) trial confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit ( >; 1-year) of this strategy in older patients is debated. To address this, an individual...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 1. doi: 10.1161/CIRCULATIONAHA.124.071493. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Complete revascularization is the standard treatment for patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. The Functional Assessment in Elderly MI Patients with Multivessel Disease (FIRE) trial confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit ( >; 1-year) of this strategy in older patients is debated. To address this, an individual patient data meta-analysis was conducted in STEMI patients aged 75 years or older enrolled in randomized clinical trials investigating complete vs. culprit-only revascularization strategies. <b>Methods:</b> PubMed, Embase, and the Cochrane database, were systematically searched to identify randomized clinical trials comparing complete vs. culprit-only revascularization. Individual patient-level data were collected from the relevant trials. The primary endpoint was death, myocardial infarction (MI), or ischemia-driven revascularization. The secondary endpoint was cardiovascular death or myocardial infarction. <b>Results:</b> Data from seven RCTs, encompassing 1733 patients (917 randomized to culprit-only and 816 to complete revascularization), were analyzed. The median age was 79 [77-83] years. Females were 595 (34%). Follow-up ranged from a minimum of six months to a maximum of 6.2 years (median 2.5 [1-3.8] years). Complete revascularization reduced the primary endpoint up to four years (HR 0.78, 95%CI 0.63-0.96), but not at the longest available follow-up (HR 0.83, 95%CI 0.69-1.01). Complete revascularization significantly reduced the occurrence of cardiovascular death or MI at the longest available follow-up (HR 0.76, 95%CI 0.58-0.99). This was observed even when censoring the follow-up at each year. Long-term rate of death did not differ between complete and culprit-only revascularization arms. <b>Conclusions:</b> In this individual patient data meta-analysis of older STEMI patients with multivessel disease, complete revascularization reduced the primary endpoint of death, MI or ischemia-driven revascularization up to 4-year. At the longest follow-up, complete revascularization reduced the composite of cardiovascular death or MI, but not the primary endpoint. <b>Clinical Study Registration:</b> PROSPERO CRD42022367898.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217603/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217603</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071493>10.1161/CIRCULATIONAHA.124.071493</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217603</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gianluca Campo</dc:creator>
<dc:creator>Feix Böhm</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Pieter C Smits</dc:creator>
<dc:creator>Islam Y Elgendy</dc:creator>
<dc:creator>Gerry McCann</dc:creator>
<dc:creator>David Wood</dc:creator>
<dc:creator>Matteo Serenelli</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Dan Eik Høfsten</dc:creator>
<dc:creator>Bianca Boxma-de Klerk</dc:creator>
<dc:creator>Adrian Banning</dc:creator>
<dc:creator>John A Cairns</dc:creator>
<dc:creator>Rita Pavasini</dc:creator>
<dc:creator>Goran Stankovic</dc:creator>
<dc:creator>Petr Kala</dc:creator>
<dc:creator>Henning Kelbæk</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Ilija Srdanovic</dc:creator>
<dc:creator>Mohamed Hamza</dc:creator>
<dc:creator>Amerjeet S Banning</dc:creator>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:creator>Shamir Mehta</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Complete vs. Culprit-Only Revascularization in Older Patients with ST-segment Elevation Myocardial Infarction: An Individual Patient Meta-Analysis</dc:title>
<dc:identifier>pmid:39217603</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071493</dc:identifier>
</item>
<item>
<title>From Setbacks to Success: Building a Promising Path for Strain-Guided Cardioprotection during Anthracycline Treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae598. doi: 10.1093/eurheartj/ehae598. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217602</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae598>10.1093/eurheartj/ehae598</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217602</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ana Barac</dc:creator>
<dc:creator>Lauren Mauro</dc:creator>
<dc:creator>Kathleen Harnden</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>From Setbacks to Success: Building a Promising Path for Strain-Guided Cardioprotection during Anthracycline Treatment</dc:title>
<dc:identifier>pmid:39217602</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae598</dc:identifier>
</item>
<item>
<title>Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217601/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with isolated GLS reduction after anthracyclines, cardioprotection is associated with better preservation of 12-month MRI-LVEF compared with usual care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 1:ehae574. doi: 10.1093/eurheartj/ehae574. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The detection of cancer therapy-related cardiac dysfunction (CTRCD) by reduction of left ventricular ejection fraction (LVEF) during chemotherapy usually triggers the initiation of cardioprotective therapy. This study addressed whether the same approach should be applied to patients with worsening of global longitudinal strain (GLS) without attaining thresholds of LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes (SUCCOUR-MRI) was a prospective multicentre randomized controlled trial involving 14 sites. Of 355 patients receiving anthracyclines with normal baseline LVEF, 333 patients (age 59±13 years, 79% women) with at least one other CTRCD risk factor, able to undergo magnetic resonance imaging (MRI), GLS and 3D echocardiography were tracked over 12 months. A total of 105 patients (age 59±13 years, 75% women, 69% breast cancer) developing GLS-CTRCD (>;12% relative reduction of GLS without a change in LVEF) between cardioprotection with neurohormonal antagonists versus usual care were randomized. The primary endpoint was 12-month change in MRI-LVEF; the secondary endpoint was MRI LVEF-defined CTRCD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During follow-up, 2 patients died and 2 developed heart failure. Most patients were randomized at 3 months (62%). Median doses of angiotensin inhibition/blockade and beta-blockade were 75% and 50% of respective targets; 21 (43%) had side-effects attributed to cardioprotection. Due to a smaller LVEF change from baseline with cardioprotection than usual care (-2.5±5.4% vs -5.6±5.9%, p=0.009), follow-up LVEF was higher after cardioprotection (59±5% vs 55±6%, p&lt;0.0001). After adjustment for baseline LVEF, the mean (95% confidence interval) difference in the change in LVEF between the two groups was -3.6% (-1.8% to -5.5%, p&lt;0.001). After cardioprotection, 1/49 patients developed 12-month LVEF-CTRCD, compared to 6/56 in usual care (p=0.075). GLS improved at 3 months post-randomization in the cardioprotection group, with little change with usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with isolated GLS reduction after anthracyclines, cardioprotection is associated with better preservation of 12-month MRI-LVEF compared with usual care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217601/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217601</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae574>10.1093/eurheartj/ehae574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217601</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas H Marwick</dc:creator>
<dc:creator>Elizabeth Dewar</dc:creator>
<dc:creator>Mark Nolan</dc:creator>
<dc:creator>Mitra Shirazi</dc:creator>
<dc:creator>Peter Dias</dc:creator>
<dc:creator>Leah Wright</dc:creator>
<dc:creator>Ben Fitzgerald</dc:creator>
<dc:creator>Leighton Kearney</dc:creator>
<dc:creator>Piyush Srivastava</dc:creator>
<dc:creator>John Atherton</dc:creator>
<dc:creator>Kazuaki Negishi</dc:creator>
<dc:creator>Aaron L Sverdlov</dc:creator>
<dc:creator>Sudhir Wahi</dc:creator>
<dc:creator>James Otton</dc:creator>
<dc:creator>Joseph Selvanayagam</dc:creator>
<dc:creator>Liza Thomas</dc:creator>
<dc:creator>Paaladinesh Thavendiranathan</dc:creator>
<dc:creator>SUCCOUR-MRI investigators</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial</dc:title>
<dc:identifier>pmid:39217601</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae574</dc:identifier>
</item>
<item>
<title>Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08194-4. doi: 10.1016/j.jacc.2024.08.022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217575</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.022>10.1016/j.jacc.2024.08.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217575</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Helen M Colhoun</dc:creator>
<dc:creator>Dror Dicker</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>Steven E Kahn</dc:creator>
<dc:creator>Alexandra Kautzky-Willer</dc:creator>
<dc:creator>Ildiko Lingvay</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Naveen Rathor</dc:creator>
<dc:creator>Søren Tetens Hoff</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex</dc:title>
<dc:identifier>pmid:39217575</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.022</dc:identifier>
</item>
<item>
<title>Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results indicate that a broader application of M-TEER in addition to optimal guideline-directed medical therapy should be considered among patients with symptomatic HF and moderate to severe FMR, particularly in those with a history of a recent hospitalization for HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 30:S0735-1097(24)08233-0. doi: 10.1016/j.jacc.2024.08.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before undergoing M-TEER.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients with Clinically Significant Functional Mitral Regurgitation) included patients with symptomatic HF and moderate to severe FMR (mean effective regurgitant orifice area 0.25 cm<sup>2</sup>; 14% >;0.40 cm<sup>2</sup>, 23% &lt;0.20 cm<sup>2</sup>) and showed that M-TEER reduced recurrent HF hospitalizations with and without the addition of cardiovascular (CV) death and improved quality of life. We now report the results of prespecified analyses on hospitalization rates and for the subgroup of patients (n = 333) with a HF hospitalization in the 12 months before randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 24 months, the time to first event of CV death or HF hospitalization (HR: 0.65; 95% CI: 0.49-0.85; P = 0.002), the rate of recurrent CV hospitalizations (rate ratio [RR]: 0.75; 95% CI: 0.57-0.99; P = 0.046), the composite rate of recurrent CV hospitalizations and all-cause mortality (RR: 0.74; 95% CI: 0.57-0.95; P = 0.017), and of recurrent CV death and CV hospitalizations (RR: 0.76; 95% CI: 0.58-0.99; P = 0.040), were all lower in the M-TEER group. The RR of recurrent hospitalizations for any cause was 0.82 (95% CI: 0.63-1.07; P = 0.15) for patients in the M-TEER group vs control group patients. Patients randomized to M-TEER lost fewer days due to death or HF hospitalization (13.9% [95% CI: 13.0%-14.8%] vs 17.4% [95% CI: 16.4%-18.4%] of follow-up time; P &lt; 0.0001, and 1,067 vs 1,776 total days lost; P &lt; 0.0001). Patients randomized to M-TEER also had better NYHA functional class at 30 days and at 6, 12, and 24 months of follow-up (P &lt; 0.0001). A history of HF hospitalizations before randomization was associated with worse outcomes and greater benefit with M-TEER on the rate of the composite of recurrent HF hospitalizations and CV death (P<sub>interaction</sub> = 0.03) and of recurrent HF hospitalizations within 24 months (P<sub>interaction</sub> = 0.06).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results indicate that a broader application of M-TEER in addition to optimal guideline-directed medical therapy should be considered among patients with symptomatic HF and moderate to severe FMR, particularly in those with a history of a recent hospitalization for HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217574</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.027>10.1016/j.jacc.2024.08.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217574</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Monika Diek</dc:creator>
<dc:creator>Jutta Heinrich</dc:creator>
<dc:creator>Martin Geyer</dc:creator>
<dc:creator>Marius Placzek</dc:creator>
<dc:creator>Roberto Ferrari</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>Ottavio Alfieri</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Wilhelm Haverkamp</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Karl-Heinz Kuck</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Vlasis Ninios</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Ulrich Schäfer</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Konstantinos Spargias</dc:creator>
<dc:creator>Alec Vahanian</dc:creator>
<dc:creator>Jose Luis Zamorano</dc:creator>
<dc:creator>Andreas Zeiher</dc:creator>
<dc:creator>Mahir Karakas</dc:creator>
<dc:creator>Friedrich Koehler</dc:creator>
<dc:creator>Mitja Lainscak</dc:creator>
<dc:creator>Alper Öner</dc:creator>
<dc:creator>Nikolaos Mezilis</dc:creator>
<dc:creator>Efstratios K Theofilogiannakos</dc:creator>
<dc:creator>Ilias Ninios</dc:creator>
<dc:creator>Michael Chrissoheris</dc:creator>
<dc:creator>Panagiota Kourkoveli</dc:creator>
<dc:creator>Konstantinos Papadopoulos</dc:creator>
<dc:creator>Grzegorz Smolka</dc:creator>
<dc:creator>Wojciech Wojakowski</dc:creator>
<dc:creator>Krzysztof Reczuch</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:creator>Łukasz Wiewiórka</dc:creator>
<dc:creator>Witold Streb</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Evelyn Santiago-Vacas</dc:creator>
<dc:creator>Tobias Friedrich Ruf</dc:creator>
<dc:creator>Michael Gross</dc:creator>
<dc:creator>Joern Tongers</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Wolfgang Schillinger</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2</dc:title>
<dc:identifier>pmid:39217574</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.027</dc:identifier>
</item>
<item>
<title>Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients undergoing low-to-intermediate risk noncardiac surgery >;1 year after stent implantation primarily with a DES, in the setting of lower-than-expected event rates, we failed to identify a significant difference between perioperative aspirin monotherapy and no antiplatelet therapy with respect to ischemic outcomes or major bleeding. (Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery [ASSURE-DES]; NCT02797548).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08196-8. doi: 10.1016/j.jacc.2024.08.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend the perioperative continuation of aspirin in patients with coronary drug-eluting stents (DES) undergoing noncardiac surgery. However, supporting evidence is limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to compare continuing aspirin monotherapy vs temporarily holding all antiplatelet therapy before noncardiac surgery in patients with previous DES implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We randomly assigned patients who had received a DES >;1 year previously and were undergoing elective noncardiac surgery either to continue aspirin or to discontinue all antiplatelet agents 5 days before noncardiac surgery. Antiplatelet therapy was recommended to be resumed no later than 48 hours after surgery, unless contraindicated. The primary outcome was a composite of death from any cause, myocardial infarction, stent thrombosis, or stroke between 5 days before and 30 days after noncardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,010 patients underwent randomization. Among 926 patients in the modified intention-to-treat population (462 patients in aspirin monotherapy group and 464 patients in the no-antiplatelet therapy group), the primary composite outcome occurred in 3 patients (0.6%) in the aspirin monotherapy group and 4 patients (0.9%) in the no antiplatelet group (difference, -0.2 percentage points; 95% CI: -1.3 to 0.9; P >; 0.99). There was no stent thrombosis in either group. The incidence of major bleeding did not differ significantly between groups (6.5% vs 5.2%; P = 0.39), whereas minor bleeding was significantly more frequent in the aspirin group (14.9% vs 10.1%; P = 0.027).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients undergoing low-to-intermediate risk noncardiac surgery >;1 year after stent implantation primarily with a DES, in the setting of lower-than-expected event rates, we failed to identify a significant difference between perioperative aspirin monotherapy and no antiplatelet therapy with respect to ischemic outcomes or major bleeding. (Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery [ASSURE-DES]; NCT02797548).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217573</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.024>10.1016/j.jacc.2024.08.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217573</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Sang-Hyup Lee</dc:creator>
<dc:creator>Se-Whan Lee</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Choongki Kim</dc:creator>
<dc:creator>Ji-Yong Jang</dc:creator>
<dc:creator>Nihar Mehta</dc:creator>
<dc:creator>Jun-Hyok Oh</dc:creator>
<dc:creator>Young Rak Cho</dc:creator>
<dc:creator>Kyung Ho Yoon</dc:creator>
<dc:creator>Sung Gyun Ahn</dc:creator>
<dc:creator>Jung-Hee Lee</dc:creator>
<dc:creator>Deok-Kyu Cho</dc:creator>
<dc:creator>Yongcheol Kim</dc:creator>
<dc:creator>Jeongsu Kim</dc:creator>
<dc:creator>Gyeong Hun Cho</dc:creator>
<dc:creator>Kyu-Sup Lee</dc:creator>
<dc:creator>Hanbit Park</dc:creator>
<dc:creator>Mutlu Vural</dc:creator>
<dc:creator>Young-Hyo Lim</dc:creator>
<dc:creator>Kyoung-Ha Park</dc:creator>
<dc:creator>Bong-Ki Lee</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Hyun-Woo Park</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Jae-Hwan Lee</dc:creator>
<dc:creator>Seung-Yul Lee</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Hyun Kuk Kim</dc:creator>
<dc:creator>Si-Hyuck Kang</dc:creator>
<dc:creator>Jae-Hyoung Park</dc:creator>
<dc:creator>In-Cheol Choi</dc:creator>
<dc:creator>Chang Sik Yu</dc:creator>
<dc:creator>Sung-Cheol Yun</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>ASSURE DES Investigators</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery</dc:title>
<dc:identifier>pmid:39217573</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.024</dc:identifier>
</item>
<item>
<title>Mechanistic Insights of SGLT2 Inhibition in Heart Failure Through Proteomics: Appreciating the Cardiovascular-Kidney Connection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39217572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240902100936&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 12:S0735-1097(24)08016-1. doi: 10.1016/j.jacc.2024.07.030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39217572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240902100936&v=2.18.0.post9+e462414">39217572</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.030>10.1016/j.jacc.2024.07.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39217572</guid>
<pubDate>Sun, 01 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi B Patel</dc:creator>
<dc:date>2024-09-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mechanistic Insights of SGLT2 Inhibition in Heart Failure Through Proteomics: Appreciating the Cardiovascular-Kidney Connection</dc:title>
<dc:identifier>pmid:39217572</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.030</dc:identifier>
</item>





























</channel>
</rss>